FMC Corporation's fluindapyr fungicide receives U.S. EPA registration

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- 

FMC Corporation (NYSE: FMC), a leading agricultural sciences company, received U.S. Environmental Protection Agency (EPA) registration for fluindapyr, a novel broad-spectrum succinate dehydrogenase inhibitor (SDHI) fungicide. Fluindapyr provides broad-spectrum activity against a wide range of destructive diseases in row and specialty crops, as well as turf.

"Fluindapyr is the result of nearly 10 years of research and development," said Dr. Kathleen Shelton, FMC vice president and chief technology officer. "This is the first significant regulatory approval for this new fungicide. To date, we have submitted for registration of fluindapyr formulations in multiple countries, including China, Brazil, Argentina, and the European Union, covering key markets in every region."

Upon the grant of these registrations, farmers around the world will have access to fluindapyr for preventative control of various fungal diseases in row crops, including multiple rust diseases in cereals and soybeans, as well as powdery mildew in specialty crops. Studies show fluindapyr controls pathogens that are resistant to other chemical classes.

In addition, golf course superintendents in the U.S. will have the flexibility to tackle destructive diseases such as Bipolaris Leaf Spot, Take-All Root Rot and Large Patch in warm-season turf, as well as Anthracnose, Fairy Ring and Dollar Spot in cool-season turfgrasses with FMC's new Kalida™ fungicide, a combination of fluindapyr and flutriafol.  Kalida™ fungicide fits extremely well in turfgrass disease management programs, allowing superintendents to rotate chemistry and achieve outstanding results. This offering follows the company's highly successful launch of Rayora™ fungicide, a stand-alone flutriafol product for use on golf course turf.

"We are excited to provide growers and golf course superintendents with a valuable new fungicide active ingredient to rotate into their disease management program," said Diane Allemang, FMC vice president and chief marketing officer. "Broad-spectrum disease control is important as multiple diseases can attack at the same time. Our research demonstrates that fluindapyr is an effective fungicide that is an excellent mixture partner to other fungicide active ingredients and is compatible with best-in-class disease management programs. FMC will bring to market high-performance fluindapyr premixture products that provide flexible and versatile resistance management with superior performance on key tough-to-control diseases. FMC fluindapyr brands will provide growers across the globe the flexibility and versatility to customize their programs as they see fit, treat multiple crops and export their crops freely."

About FMC

FMC Corporation, an agricultural sciences company, provides innovative solutions to growers around the world with a robust product portfolio fueled by a market-driven discovery and development pipeline in crop protection, plant health, and professional pest and turf management. This powerful combination of advanced technologies includes leading insect control products based on Rynaxypyr^® and Cyazypyr^® active ingredients; Authority^®, Boral^®, Centium^®, Command^® and Gamit^® branded herbicides; Talstar^® and Hero^® branded insecticides; and flutriafol-based fungicides. The FMC portfolio also includes biologicals such as Quartzo^® and Presence^® bionematicides. FMC Corporation employs approximately 6,400 employees around the globe. To learn more, please visit www.fmc.com.

FMC, the FMC logo, Rynaxypyr, Cyazypyr, Authority, Boral, Centium, Command, Gamit, Talstar, Hero, Quartzo, Presence, Rayora and Kalida are trademarks of FMC Corporation or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. Hero^® insecticide is a restricted use pesticide in the United States.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained herein, in FMC's other filings with the SEC, and in reports or letters to FMC stockholders.

In some cases, FMC has identified forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on management's current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Currently, one of the most significant factors is the potential adverse effect of the current COVID-19 pandemic on the financial condition, results of operations, cash flows and performance of FMC, which is substantially influenced by the potential adverse effect of the pandemic on FMC's customers and suppliers and the global economy and financial markets. The extent to which COVID-19 impacts us will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others.  Additional factors include, among other things, the risk factors and other cautionary statements included within FMC's 2020 Form 10-K filed with the SEC as well as other SEC filings and public communications. Moreover, investors are cautioned to interpret many of these factors as being heightened as a result of the ongoing and numerous adverse impacts of the COVID-19 pandemic.

FMC cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. FMC undertakes no obligation, and specifically disclaims any duty, to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fmc-corporations-fluindapyr-fungicide-receives-us-epa-registration-301307667.html

SOURCE FMC Corporation